A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors

As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...

Full description

Bibliographic Details
Main Authors: Aerin Yoon, Shinai Lee, Sua Lee, Sojung Lim, Yong-Yea Park, Eunjung Song, Dong-Sik Kim, Kisu Kim, Yangmi Lim
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Biomolecules
Subjects:
mesothelin
cd3
bispecific antibody
solid tumor
cancer immunotherapy
t cell-engaging
heterodimeric bivalent
heterodimeric trivalent
tumor regression
Online Access:https://www.mdpi.com/2218-273X/10/3/399

Internet

https://www.mdpi.com/2218-273X/10/3/399

Similar Items